Drug Watch

A panel of experts presented new consensus recommendations focused on the screening, diagnosis, and treatment of tardive dyskinesia among older adults in long-term care settings.

Tazbentetol interim results show improvement in schizophrenia symptoms.

LB Pharmaceuticals has initiated the pivotal phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia.

AD/PD 2026 highlights oral blarcamesine preserving brain volume and IV lecanemab sustaining use while clearing amyloid-beta.

Intranasal BPL-003 shows rapid, sustained depression relief in treatment-resistant patients.

Phase 2 study tests AL001 brain-targeted lithium in bipolar I, aiming to cut toxicity and monitoring via advanced MRI/MRS imaging.

Guy Goodwin, MD, provides insights into COMP360 psilocybin and recent trial results, as well as psychedelics as a whole and their role in psychiatry.

New phase 2 data show HLP004 boosts standard antidepressants for moderate-to-severe GAD.

Phase 2 trial finds BXCL501 eases methadone-taper opioid withdrawal, outperforming lofexidine with simpler dosing and fewer adverse effects.

Check out the pipeline updates from February!

FDA clears Bysanti, a novel atypical antipsychotic for acute bipolar I and schizophrenia, leveraging Fanapt data; US launch planned 2026.

The FDA accepts Teva’s once-monthly olanzapine injection for schizophrenia, promising steadier adherence without mandatory 3-hour monitoring.

FDA feedback for CYC-126: anesthetic therapy with live EEG guidance aims to deliver precise relief for treatment-resistant depression.

IV DMT psychedelic SPL026 reduces major depression in phase 2a.

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

FDA reviews INmune Bio’s biomarker-enriched Phase 2b/3 plan for XPro1595.

Data and Safety Monitoring Board finds no safety issues for buntanetap at 6 months, keeping Annovis’ phase 3 early Alzheimer disease trial on track as enrollment progresses.

A new liquid stimulant option promises up to 14-hour ADHD symptom control and flexible dosing for adults and kids who struggle with capsule medication.

Denovo teams with Orygen to test DB103, a glutamate-targeting therapy, in a phase 2 youth trial for early psychosis.

FDA grants priority review to Takeda’s orexin agonist oveporexton, promising phase 3 gains in wakefulness and cataplexy for narcolepsy type 1.

Cognition extends zervimesine expanded access for Lewy body dementia, adding months of dosing and easier local monitoring.

Preclinical mGlu7 negative allosteric modulator ADX71743 disrupts fear-memory reconsolidation.

Check out the pipeline updates from January!

The FDA has accepted for priority review an NDA for Otsuka's centanafadine, a novel ADHD treatment.